Bramah N SinghShow email address
Clinical Professor of Medicine, UMDNJ-Robert Wood Johnson School of Medicine, Piscataway, New Jersey | Professor of Clinical Cardiology, Department of Cardiac and Vascular ...
Is this your profile? Claim your profile Copy URL Embed Link to your profile
Bramah N Singh:Expert Impact
Concepts for whichBramah N Singhhas direct influence:Atrial fibrillation,Sinus rhythm,Heart rate,Cardiac arrhythmias,Heart failure,Calcium antagonists,Atrial flutter,Circadian rhythmicity.
Bramah N Singh:KOL impact
Concepts related to the work of other authors for whichfor which Bramah N Singh has influence:Atrial fibrillation,Heart failure,Myocardial infarction,Sinus rhythm,Catheter ablation,Ventricular tachycardia,Rate control.
KOL Resume for Bramah N Singh
Clinical Professor of Medicine, UMDNJ-Robert Wood Johnson School of Medicine, Piscataway, New Jersey
VA Medical Center West, Los Angeles, California
Division of Cardiology, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA, USA,
David Geffen School of Medicine at UCLA, VA Greater Los Angeles Health Care System, Los Angeles, CA, USA
David Geffen School of Medicine at UCLA, and VA Greater Los Angeles Health Care System, 11301 Wilshire Boulevard, Los Angeles, CA 90073, USA
Veterans Affairs Medical Center–West Los Angeles, Los Angeles (B.N.S.)
University of California, Los Angeles, California
Department of Veterans Affairs Medical Center, Los Angeles, CA
West Los Angeles Veterans Affairs Medical Center, Los Angeles, Calif
+1 310 268 36 46; fax: +1 310 473 07 24. E-mail address: or
From the Veterans Affairs Greater Los Angeles Healthcare System and the David Geffen School of Medicine at UCLA — both in Los Angeles (B.N.S.)
Cardiology Division, VA Greater Los Angeles Healthcare System, 11301 Wilshire Boulevard, 90073, West Los Angeles, CA, USA
Department of Veterans Affairs Medical Center, West Los Angeles, California
Director of Electrophysiology, St. Michael's Hospital, Toronto, Ontario, Canada
Professor, Department of Pharmacology and the Center for Molecular Therapeutics, Columbia University, New York, New York
Professor of Clinical Cardiology, St. George's Hospital Medical School, London, United Kingdom
David Geffen School of Medicine at UCLA and the Greater Los VA Healthcare System, West Los Angeles, Los Angeles, CA
Department of Medicine, University of California, Los Angeles
David Geffen School of Medicine at UCLA and the Veterans Administration Greater Los Angeles Healthcare System
Attending Physician, University Hospital, Wishard Memorial Hospital, Roudebush Veterans Affairs Hospital, Methodist Hospital, Indianapolis, Indiana
Professor and Chair, Department of Pharmacology
Director, Institute for Cardiovascular Research, SUNY Upstate Medical University, Syracuse, New York
Department of Cardiology VA Medical Center, West Los Angeles, and UCLA School of Medicine, Los Angeles, California 90073, USA.
Veterans Affairs Hospital, West Los Angeles, California, USA
Department of Cardiology VA Medical Center, West Los Angeles, Los Angeles, CA 90073, USA.
UCLA School of Medicine and the Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, CA; Division of Cardiology, Greater Los Angles Veterans Healthcare System, 11301 Wilshire Boulevard, Los Angeles, CA 90073
Cardiovascular Research Lab at VA Medical Center, University of California at Los Angeles, School of Medicine, Los Angeles, CA.
Division of Cardiology 111E, VA Medical Center of West Los Angeles, 11301 Wilshire Boulevard, 90073, Los Angeles, CA, USA
From the University of Iowa, Iowa City, IA*; St. Michael’s Hospital, Toronto, Ontario, Canada‡; Medical College of Virginia, Richmond, VA§; Amsterdam, Netherlands∥; University of Washington Medical Center, Seattle, WA¶; University of Minnesota Medical School, Minneapolis, MN#; Royal Melbourne Hospital, Victoria, Australia**; The Royal Infirmary of Edinburgh, Edinburgh, UK‡‡; University of Arizona, Tucson, AZ§§; University of Southern California, Los Angeles, CA∥∥; and University of California, Los Angeles, CA.¶¶
Department of Cardiology VA Medical Center, West Los Angeles, and Department of Medicine, UCLA Mecdical Center, and UCLA School of Medicine, Los Angeles, CA
University of California Los Angeles School of Medicine, Los Angeles, California
Section of Cardiology, Departments of Medicine, VA Medical Center of West Los Angeles and UCLA School of Medicine, Los Angeles, CA
Wadsworth VA Hospital, Los Angeles, California, USA
Veterans Affairs Medical Center of West Los Angeles and UCLA School of Medicine, Los Angeles, California
From the Cardiovascular Research Laboratory, Section of Cardiology, VA Medical Center of West Los Angeles and UCLA School of Medicine, Los Angeles, Calif.
Division of Cardiology, Veterans Affairs Medical Center of West Los Angeles; and the University of California-Los Angeles School of Medicine, Los Angeles, California, USA.
From University of California, San Francisco School of Medicine, Fresno, Calif (P.C.D.); Stanford University, Stanford, Calif (P.C.D.); Veterans Affairs Medical Center, Fresno (P.C.D.), Los Angeles (B.N.S.), Richmond (K.E.), and Washington, DC (S.N.S., R.F.); Medical College of Virginia, Richmond (K.E.), and Cooperative Studies Program, Hines, Ill (S.F.).
Veterans Affairs Medical Center, Washington, DC, USA
Department of Medicine, UCLA School of Medicine, Department of Cardiology, VA Medical Center of West Los Angeles, California
Division of Cardiology 111E, VAMC of West Los Angeles. 11301 Wilshire Boulevard, Los Angeles, CA 90073.
Veterans Affairs Medical Center of Los Angeles and the UCLA School of Medicine, Los Angeles, California, USA
Division of Cardiology and the Department of Medicine, Veterans Affairs Medical Center and the Department of Medicine, UCLA School of Medicine, Los Angeles, California
From Zagazig University, Zagazig, Egypt
VAMC/Fresno & Washington
Department of Cardiology, Wadsworth Veterans Affairs Medical Center, Los Angeles (B.N.S.)
From the Cardiovascular Division, Department of Medicine, Veterans Affairs Medical Center of West Los Angeles Los Angeles, California U.S.A.
Division of Cardiology, Veterans Affairs Medical Center of West Los Angeles Los Angeles, Calif., USA
|marked depressant conduction||#1|
|homogeneity ventricular repolarization||#1|
|ventricular repolarization refractoriness||#1|
|mortality cardiovascular disorders||#1|
|marked shortening apd||#1|
|cardiac arrhythmias repolarization||#1|
|119 26 msec||#1|
|bepridil therapy guidelines||#1|
|nitroglycerin consumption groups||#1|
|triggered potentials development||#1|
|drug heart rate||#1|
|hemodynamic beta blockers||#1|
|antifibrillatory drugs cibis||#1|
|qtc dispersions patients||#1|
|electrical instability years||#1|
|lesser degree flecainide||#1|
|myocardium liver kidney||#1|
|sotalol purkinje fibers||#1|
|conventional regimen quinidine||#1|
|frequency range nadolol||#1|
|3 agents verapamil||#1|
|marked sympathomimetic activity||#1|
|agents beta blockers||#1|
|arrhythmia agents arrhythmias||#1|
|sotalol biphasic response||#1|
|drug 3 weeks||#1|
|upstream therapies statins||#1|
|amiodarone ventricular arrhythmias||#1|
|vrp plasma level||#1|
|focus mortality reduction||#1|
|torsade pointes setting||#1|
|Sign-in to see all concepts, it's free!|
Prominent publications by Bramah N Singh
[ PUBLICATION ]
SynopsisSotalol1 is a β- adrenoceptor blocking agent devoid of intrinsic sympathomimetic activity, membrane stabilising actions and cardioselectivity. It lengthens repolarisation and the effective refractory period in all cardiac tissues independently of its antiadrenergic properties. Combining Class II and Class III antiarrhythmic properties, sotalol can be given either intravenously or orally and its pharmacokinetic properties permit long dosing (once or twice daily) ...
|Known for Patients Sotalol | Drug Heart Rate | Torsade Pointes | Β Blockers | Action Potential Duration|
Synopsis: Verapamil is a novel antiarrhythmic and antianginal agent which, although introduced in 1962, has only recently gained prominence not only as a significant agent in cardiovascular therapeutics but also as a powerful tool to examine the nature of some of the biophysical phenomena at the membrane of cardiac and other excitable tissues. Verapamil is the prototype of those agents which selectively inhibit membrane transport of calcium, an action which accounts for the drug’s ...
|Known for Pharmacological Properties | Verapamil Drug | Atrial Fibrillation | Sinus Rhythm | Angina Hypertension|
[ PUBLICATION ]
Synopsis: Mexiletine2 is a new local anaesthetic antiarrhythmic agent whose chemical structure and electrophysiological properties closely resemble those of lignocaine although its anticonvulsant and pharmacokinetic properties differ from that drug. Unlike lignocaine (lidocaine) it is active following oral administration with a plasma half-life varying between 8 and 20 hours so that it can be administered twice or three times daily to sustain therapeutic plasma levels. The drug is ...
|Known for Mexiletine Patients | Ventricular Arrhythmias | Acute Myocardial Infarction | Effective Refractory Period | Oral Administration|
[ PUBLICATION ]
Synopsis: Acebutolol1 is a cardioselective β-adrenoceptor blocking drug possessing both partial agonist (intrinsic sympathomimetic) and membrane stabilising activity. In hypertension, it can be administered once or twice daily with equal effectiveness, and has been as effective at lowering blood pressure as propranolol, diuretics, and other β-blocking drugs (metoprolol, labetalol and atenolol) and more effective than methyldopa. Acebutolol has a significantly smaller effect on resting ...
|Known for Acebutolol Propranolol | Atenolol Metoprolol | Heart Rate | Blood Pressure | Blocking Drugs|
BACKGROUND: It is common practice to restore and maintain sinus rhythm in patients with atrial fibrillation and heart failure. This approach is based in part on data indicating that atrial fibrillation is a predictor of death in patients with heart failure and suggesting that the suppression of atrial fibrillation may favorably affect the outcome. However, the benefits and risks of this approach have not been adequately studied.
METHODS: We conducted a multicenter, randomized trial ...
|Known for Rhythm Control | Atrial Fibrillation | Heart Failure | Death Patients | Ventricular Rate|
Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation
[ PUBLICATION ]
BACKGROUND: In a multicenter, double-blind, placebo-controlled study, the long-term effects of amiodarone on morbidity and mortality in patients with congestive heart failure (CHF) and atrial fibrillation (AF) were evaluated during a 4-year period.
METHODS AND RESULTS: Of 667 patients with CHF, 103 (15%) had AF at baseline. Of these, 51 were randomized to amiodarone and 52 to placebo. The group with sinus rhythm and the group in AF were comparable except for a higher proportion of AF in ...
|Known for Sinus Rhythm | Amiodarone Patients | Atrial Fibrillation | Heart Failure | Spontaneous Conversion|
[ PUBLICATION ]
BACKGROUND: Asymptomatic ventricular arrhythmias in patients with congestive heart failure are associated with increased rates of overall mortality and sudden death. Amiodarone is now used widely to prevent ventricular tachycardia and fibrillation. We conducted a trial to determine whether amiodarone can reduce overall mortality in patients with congestive heart failure and asymptomatic ventricular arrhythmias.
METHODS: We used a double-blind, placebo-controlled protocol in which 674 ...
|Known for Amiodarone Patients | Congestive Heart Failure | Ventricular Arrhythmia | Mortality Sudden Death | Nonischemic Cardiomyopathy|
Left ventricular ejection fraction determined by radionuclide ventriculography in early stages of first transmural myocardial infarction Relation to short-term prognosis
[ PUBLICATION ]
Left ventricular ejection fraction was determined with multiple gated equilibrium cardiac blood pool scintigraphy within 24 hours of the onset of symptoms of a first acute transmural myocardial infarction in 56 patients (23 with anterior and 33 with inferior infarction). A depressed ejection fraction (less than 0.54) was more frequent in patients with anterior (96 percent) than in those with inferior (61 percent) infarction (p <0.001); the mean ejection fraction was lower in patients ...
|Known for Ejection Fraction | Myocardial Infarction | Hospital Patients | Term Prognosis | Heart Failure|
Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
[ PUBLICATION ]
BACKGROUND: Recent data have suggested that antiarrhythmic agents that act largely by delaying conduction may not be as effective in controlling ventricular arrhythmias as those that prolong repolarization. Recently, numerous "pure" class III agents have been developed.
METHODS AND RESULTS: The antiarrhythmic and electrophysiologic profiles of sematilide, a "pure" class III agent, were determined in 27 patients with clinical ventricular arrhythmias and inducible sustained ventricular ...
|Known for Ventricular Tachycardia | Selective Prolongation | Refractory Period | Antiarrhythmic Effects | Electrophysiologic Study|
Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina
[ PUBLICATION ]
The Nifedipine Gastro-Intestinal Therapeutic System (GITS) Circadian Anti-ischemia Program (N-CAP) was designed to test the effect of nifedipine GITS as monotherapy or in combination with a beta-adrenergic blocking agent on the circadian pattern of angina and silent ischemia in patients with chronic stable angina. At 118 sites in the United States, 1,174 patients were screened for entry into this study. To be eligible for participation patients were required to have at least two episodes ...
|Known for Nifedipine Gits | Myocardial Ischemia | Chronic Stable Angina | Circadian Pattern | Single Blind|
[ PUBLICATION ]
BACKGROUND: The optimal pharmacologic means to restore and maintain sinus rhythm in patients with atrial fibrillation remains controversial.
METHODS: In this double-blind, placebo-controlled trial, we randomly assigned 665 patients who were receiving anticoagulants and had persistent atrial fibrillation to receive amiodarone (267 patients), sotalol (261 patients), or placebo (137 patients) and monitored them for 1 to 4.5 years. The primary end point was the time to recurrence of atrial ...
|Known for Atrial Fibrillation | Amiodarone Sotalol | Sinus Rhythm | Patients Placebo | Quality Life|
Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: Potent suppression of spontaneously occurring tachyarrhythmias versus in
[ PUBLICATION ]
The antiarrhythmic efficacy and the electrophysiologic effects of amiodarone were determined in 13 consecutive patients with symptomatic life-threatening ventricular arrhythmias resistant to conventional agents. Amiodarone was initially given in high doses (1000 to 1800 mg/daily); electrophysiologic effects including induction of ventricular tachycardia (VT) by programmed electrical stimulation (PES) was undertaken before and after a mean period of 28 (range 14 to 56) days of amiodarone ...
|Known for Antiarrhythmic Efficacy | Ventricular Tachycardia | Electrophysiologic Actions | Amiodarone Patients | Induction Pes|
Advantages of beta blockers versus antiarrhythmic agents and calcium antagonists in secondary prevention after myocardial infarction
[ PUBLICATION ]
Patients who have sustained greater than or equal to 1 myocardial infarcts are at high risk for sudden death or reinfarction; the risk is highest for those with lowest ventricular ejection fraction, continuing myocardial ischemia and asymptomatic high-density and complex premature ventricular contractions. At present, beta blockers when given prophylactically are the only agents that reduce the incidence of sudden death and reinfarction in survivors of myocardial infarction (MI) in the ...
|Known for Beta Blockers | Myocardial Infarction | Antiarrhythmic Agents | Calcium Antagonists | Mortality Survivors|
Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease
[ PUBLICATION ]
The effects of verapamil, 0.145 mg/kg body weight, administered intravenously in a bolus injection followed by 0.005 mg/kg per min, on cardiovascular hemodynamics and on ventricular ejection fraction, determined with gated cardiac blood pool scanning, were studted in 25 patients, 8 with acute myocardial infarction and 17 with symptomatic coronary artery disease who were undergoing diagnostic cardiac catheterization. The mean (± standard deviation) plasma verapamil level, determined with ...
|Known for Heart Disease | Stroke Volume | Ventricular Dysfunction | Ejection Fraction | Arterial Pressure|
BACKGROUND: In general, antiarrhythmic agents that prolong the action potential duration (APD) have attenuated effects on repolarization at short cycle lengths (reverse frequency dependence), and this may limit their efficacy for controlling ventricular arrhythmias. The frequency-dependent effects of amiodarone on repolarization may differ from those of other antiarrhythmic agents and have not been determined in humans.
METHODS AND RESULTS: The frequency-dependent effects of amiodarone ...
|Known for Electrophysiologic Effects | Frequency Dependent | Qrs Duration | Cycle Lengths | Ventricular Repolarization|